Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Biomarkers For Immunotherapy Of Cancer
Download Biomarkers For Immunotherapy Of Cancer full books in PDF, epub, and Kindle. Read online Biomarkers For Immunotherapy Of Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Biomarkers for Immunotherapy of Cancer by : Magdalena Thurin
Download or read book Biomarkers for Immunotherapy of Cancer written by Magdalena Thurin and published by Humana. This book was released on 2019-09-10 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides the immune oncology (IO) community with a deeper understanding of the scope of the biomarker methods to potentially improve the outcome from immunotherapy. The editors secured the input from experts in the field dedicated to translating scientific research from bench to bedside was submitted. The book provides not only details about the technical, standardization and interpretation aspects of the methods but also introduces the reader to the background information and scientific justification for selected biomarkers and assays. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Book Synopsis Immune Checkpoint Inhibitors in Cancer by : Fumito Ito
Download or read book Immune Checkpoint Inhibitors in Cancer written by Fumito Ito and published by Elsevier Health Sciences. This book was released on 2018-09-03 with total page 400 pages. Available in PDF, EPUB and Kindle. Book excerpt: Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. Helps you translate current research and literature into practical information for daily practice. Presents information logically organized by disease site. Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. Consolidates today’s available information on this timely topic into one convenient resource.
Book Synopsis Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer by : Said Dermime
Download or read book Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer written by Said Dermime and published by Frontiers Media SA. This book was released on 2021-12-28 with total page 284 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Identification of Biomarkers for Cancer Immunotherapy: From Bench to Bedside, volume I by : Chang Gu
Download or read book Identification of Biomarkers for Cancer Immunotherapy: From Bench to Bedside, volume I written by Chang Gu and published by Frontiers Media SA. This book was released on 2023-10-20 with total page 191 pages. Available in PDF, EPUB and Kindle. Book excerpt: During the past few decades, immunotherapy has become an established pillar of cancer treatment improving the survival of numerous patients with diverse solid and hematologic tumors. The leading causes behind the success are the discovery of immune checkpoint inhibitors (ICIs) and the development of chimeric antigen receptor (CAR) T/M/NK cells. As for ICIs, malignancies take advantage of the inhibitory programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) or cytotoxic T-lymphocyte-associated protein (CTLA-4) pathways to evade the immune system, and disruption of the axis by immune checkpoint inhibitors can achieve durable disease remissions, which has been proved by basic researches and (pre-) clinical studies among lung cancer, melanoma, renal cell cancer, head, and neck squamous cell carcinoma, urothelial cancer, and Hodgkin’s disease. However, the 5-year survival rate of patients treated with ICIs varies with each individual and also relies on tumor specific pathological or molecular subtypes. Besides, the efficacy of ICIs is still limited in terms of drug resistance and fewer potential responders. Thus, there is a big challenge to identify and develop more novel reliable ICIs, as well as sensibilize existing ICIs for patients with drug resistance or even for non-responders.
Book Synopsis Advancing the Science of Cancer in Latinos by : Amelie G. Ramirez
Download or read book Advancing the Science of Cancer in Latinos written by Amelie G. Ramirez and published by Springer Nature. This book was released on 2019-11-21 with total page 320 pages. Available in PDF, EPUB and Kindle. Book excerpt: This open access book gives an overview of the sessions, panel discussions, and outcomes of the Advancing the Science of Cancer in Latinos conference, held in February 2018 in San Antonio, Texas, USA, and hosted by the Mays Cancer Center and the Institute for Health Promotion Research at UT Health San Antonio. Latinos – the largest, youngest, and fastest-growing minority group in the United States – are expected to face a 142% rise in cancer cases in coming years. Although there has been substantial advancement in cancer prevention, screening, diagnosis, and treatment over the past few decades, addressing Latino cancer health disparities has not nearly kept pace with progress. The diverse and dynamic group of speakers and panelists brought together at the Advancing the Science of Cancer in Latinos conference provided in-depth insights as well as progress and actionable goals for Latino-focused basic science research, clinical best practices, community interventions, and what can be done by way of prevention, screening, diagnosis, and treatment of cancer in Latinos. These insights have been translated into the chapters included in this compendium; the chapters summarize the presentations and include current knowledge in the specific topic areas, identified gaps, and top priority areas for future cancer research in Latinos. Topics included among the chapters: Colorectal cancer disparities in Latinos: Genes vs. Environment Breast cancer risk and mortality in women of Latin American origin Differential cancer risk in Latinos: The role of diet Overcoming barriers for Latinos on cancer clinical trials Es tiempo: Engaging Latinas in cervical cancer research Emerging policies in U.S. health care Advancing the Science of Cancer in Latinos proves to be an indispensable resource offering key insights into actionable targets for basic science research, suggestions for clinical best practices and community interventions, and novel strategies and advocacy opportunities to reduce health disparities in Latino communities. It will find an engaged audience among researchers, academics, physicians and other healthcare professionals, patient advocates, students, and others with an interest in the broad field of Latino cancer.
Book Synopsis Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy, volume II by :
Download or read book Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy, volume II written by and published by Frontiers Media SA. This book was released on 2024-01-10 with total page 261 pages. Available in PDF, EPUB and Kindle. Book excerpt: This Research Topic is the second volume of the “Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy". Please see Volume I here. Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy. This research topic aims to focus on the advances in the discoveries of novel biomarkers for predicting response to cancer immunotherapy in various tumors. We welcome the submission of original research and review articles that include biomarkers in clinical study and applications, as well as technologies or discoveries in experimental approaches.
Book Synopsis Novel Biomarkers for Predicting Response to Cancer Immunotherapy by : Jinghua Pan
Download or read book Novel Biomarkers for Predicting Response to Cancer Immunotherapy written by Jinghua Pan and published by Frontiers Media SA. This book was released on 2023-07-11 with total page 493 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy.
Book Synopsis Biomarkers and Immunotherapy for Genitourinary Tumors by : Hui Dai
Download or read book Biomarkers and Immunotherapy for Genitourinary Tumors written by Hui Dai and published by Frontiers Media SA. This book was released on 2024-04-02 with total page 374 pages. Available in PDF, EPUB and Kindle. Book excerpt: Genitourinary tumors consist of a large variety of malignancies located in the urinary and the reproductive systems, mainly including prostate cancer, bladder cancer, and renal tumors. Apart from surgeries, various systemic treatments have been used for the whole-course management of genitourinary tumors, including radiation therapy, chemotherapy, and hormonal therapy. However, the characteristics of progression, metastasis, and drug resistance deriving from tumors require and breed novel treatments. Furthermore, exploring biomarkers of genitourinary tumors at the early stage is also beneficial to strengthen the management of patients with tumors. Additionally, the diagnostic and prognostic value of the potential biomarkers for immunotherapy and combined therapy of genitourinary tumors are underexplored. On the basis of precision treatments, the advent of immune-based therapies, including immune checkpoint inhibitors (ICIs, antibodies targeting PD-L1 /PD-1 and CTLA-4 pathways), tumor vaccines, and other therapies, has extended the scope of treatment modalities. FDA has until now approved the clinical application of immune checkpoint inhibitors in a wide range of diseases including some types of genitourinary tumors, whereas not all patients with genitourinary tumors are suitable for immune-based therapies, therefore, the understanding of its underlying mechanism is key to develop effective treatments based on current ICI-based immunotherapy.
Book Synopsis Immunotherapy in Translational Cancer Research by : Laurence J. N. Cooper
Download or read book Immunotherapy in Translational Cancer Research written by Laurence J. N. Cooper and published by John Wiley & Sons. This book was released on 2018-05-01 with total page 306 pages. Available in PDF, EPUB and Kindle. Book excerpt: A guide to state-of-the-art cancer immunotherapy in translational cancer research A volume in the Translational Oncology series, Immunotherapy in Translational Cancer Research explores the recent developments in the role that immunotherapy plays in the treatment of a wide range of cancers. The editors present key concepts, illustrative examples, and suggest alternative strategies in order to achieve individualized targeted therapy. Comprehensive in scope, Immunotherapy in Translational Cancer Research reviews the relevant history, current state, and the future of burgeoning cancer-fighting therapies. The book also includes critical information on drug development, clinical trials, and governmental resources and regulatory issues. Each chapter is created to feature: development of the immunotherapy; challenges that have been overcome in order to scale up and undertake clinical trials; and clinical experience and application of research. This authoritative volume is edited by a team of noted experts from MD Anderson Cancer Center, the world’s foremost cancer research and care center and: Offers a comprehensive presentation of state-of-the-art cancer immunotherapy research that accelerates the pace of clinical cancer care Filled with the concepts, examples, and approaches for developing individualized therapy Explores the breath of treatments that reflect the complexity of the immune system itself Includes contributions from a panel international experts in the field of immunotherapy Designed for physicians, medical students, scientists, pharmaceutical executives, public health and public policy government leaders and community oncologists, this essential resource offers a guide to the bidirectional interaction between laboratory and clinic immunotherapy cancer research.
Book Synopsis Identification of immunotherapy-related biomarkers for gynecological cancers by : Jinhui Liu
Download or read book Identification of immunotherapy-related biomarkers for gynecological cancers written by Jinhui Liu and published by Frontiers Media SA. This book was released on 2023-04-19 with total page 211 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Advances in Precision Medicine Oncology by : Hilal Arnouk
Download or read book Advances in Precision Medicine Oncology written by Hilal Arnouk and published by . This book was released on 2021 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects.
Book Synopsis Multi-dimensional Biomarkers and Resistance Mechanism of Targeted Therapy and Immunotherapy in Lung Cancer by : Tao Jiang
Download or read book Multi-dimensional Biomarkers and Resistance Mechanism of Targeted Therapy and Immunotherapy in Lung Cancer written by Tao Jiang and published by Frontiers Media SA. This book was released on 2022-02-02 with total page 196 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Immunotherapy of Hepatocellular Carcinoma by : Tim F. Greten
Download or read book Immunotherapy of Hepatocellular Carcinoma written by Tim F. Greten and published by Springer. This book was released on 2017-10-04 with total page 167 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
Book Synopsis Handbook of Therapeutic Biomarkers in Cancer by : Sherry X. Yang
Download or read book Handbook of Therapeutic Biomarkers in Cancer written by Sherry X. Yang and published by CRC Press. This book was released on 2021-02-01 with total page 678 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive overview of the fast-evolving subject of clinical application of cancer therapeutic biomarkers. The second edition captures significant progress of cancer immunotherapy and emphasizes the genetic basis for selective cancer treatment. It covers an in-depth insight on biomarkers across a broad area of cancer research and oncology with a wealth of integrated genetic and molecular information about specific therapies by a multidisciplinary team of internationally recognized experts. Each chapter focuses on a class of targeted, immunologic, or chemotherapy agents and their companion biomarkers that predict response, benefit or resistance, and severe adverse event. The book will serve as a handbook for health professionals and scientists on the current applicable biomarkers in the management of cancer. The vision into the systemic classification and statistical consideration of therapeutic biomarkers summarized by the book editors and chapter authors will help advance precision medicine—a precisely tailored cancer treatment strategy for cancer patient care.
Book Synopsis Precision Medicine in Oncology by : Bulent Aydogan
Download or read book Precision Medicine in Oncology written by Bulent Aydogan and published by John Wiley & Sons. This book was released on 2020-11-02 with total page 288 pages. Available in PDF, EPUB and Kindle. Book excerpt: A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working – not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others.
Book Synopsis Therapeutic Opportunities and Innovative Biomarkers in Tumor Microenvironment by : Zhenyu Jia
Download or read book Therapeutic Opportunities and Innovative Biomarkers in Tumor Microenvironment written by Zhenyu Jia and published by Frontiers Media SA. This book was released on 2022-01-19 with total page 316 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Immunotherapy written by Aung Naing and published by Springer Nature. This book was released on 2022-01-01 with total page 445 pages. Available in PDF, EPUB and Kindle. Book excerpt: The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist. Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions. The fourth edition will have a new focus on strategies to overcome the challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy.
